Sumarsono A, Vaduganathan M, Ajufo E, et al. - In this US nationwide claims-based study, researchers assessed national patterns of use of sacubitril/valsartan and ivabradine and associated therapeutic spending in Medicare Part D and Medicaid. According to results, the number of Medicare beneficiaries prescribed sacubitril/valsartan rose from 35,423 to 90,606 (156% increase from 2016 to 2017). Data reported that Medicare beneficiaries prescribed ivabradine rose from 15,856 to 23,213 (46% increase). Medicare Part D spent $227 million and $7.3 million, respectively, on sacubitril/valsartan and ivabradine in 2017. Compared with 2016 spending, it reflected increases of 241% and 59% respectively. The annual Medicare per-beneficiary spending was $2512 and $2400 on sacubitril/valsartan and ivabradine. Among Medicaid beneficiaries, parallel trends in use patterns and spending were noted. Current use of sacubitril/valsartan and ivabradine is increasing, but ongoing efforts are required to encourage high-value treatment while enhancing affordability and access to proven and new therapies for heart failure.